Akero’s New MASH Drug Data: Longer Treatment Leads to More Liver Benefit March 4, 2024 / MASH / Drug Development / Liver Disease Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance...